Analysis of the relationship between the response after the First-line chemotherapy and the survival in the advanced non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 11, Issue 3, 2008, Pages 333-338

  Lin, Liping ^a   Xiang, Xiaojuan ^a   Huang, He ^a   Zhao, Hongyun ^a   Zhang, Yang ^a   Wu, Jingxun ^a   Zhao, Yuanyuan ^a   Wu, Xuan ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Chemotherapy; Lung neoplasms; Outcome; Prognosis factor

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 47149100533     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2008.03.015     Document Type: Article

References (20)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest, 1997, 111(6): 1710-1717.
2. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non- small cell lung cancer: a meta-analysis. Lancet, 1993, 342(8862): 19-21.
3. Marino P, Pampailona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer: Results of a metaanalysis of the literature. Chest, 1994, 106(3): 861-865.
4. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ, 1995, 311: 899-909.
5. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide-cisplatin versus Taxol with cisplatin-G-CSF versus Taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group trial [abstract]. Proc Am Soc Clin Oncol, 1996, 15: 382.
6. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 2000, 18(1): 122-130.
7. Booton R, Lorigan P, Anderson H, et al. A phase III trial of docetaxel/ carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine /cis- -platin(MVP) in patients with advanced non-smallcell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group. Ann Oncol, 2006, 17(7): 1111-1119.
8. Shepherd FA. Chemotherapy for non small cell lung cancer: have we reached a new plateau? Semin Oncol, 1999, 26: 3-11.
9. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non small cell lung cancer. N Engl J Med, 2002, 346(2): 92-98.
10. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non small cell lung cancer: he TAX 326 Study Group. J Clin Oncol, 2003, 21(16): 3016-3024.
11. Cornella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol, 2000, 18(7): 1451-1457.
12. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet, 2001, 357(9267): 1478-1484.
13. Herbst RS, Khuri FR, Lu C, et al. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced non-small cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer, 2002, 95(2): 340-353.
14. Patrick Therasse, Susan G, Arbuck, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 2000, 92(3): 205-216.
15. Kurata T, Matsuo K, Takada M, et al. Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer? J Thorac Oncol, 2006, (7): 684-691.
16. Gebbia V, Galetta D, Caruso M, et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer, 2003, 39(2): 179-189.
17. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol, 2003, 21(17): 3207-3213.
18. Laack E, Dickgreber N, Müller T, et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol, 2004, 22(12): 2348-2356.
19. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst, 2007, 99(11): 847-857.
20. Hotta K, Fujiwara Y, Kiura K, et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol, 2007, 2(5): 402-407.